19 / 88
WFSBP 2017
19
Tuesday, 20 June 2017
/ Scientific Programme Schedule
Auditorium
15
Congress
Hall A3
Auditorium
12
Auditorium
10
Auditorium
11
B3 M1–M2 B3 M3–M4 Congress
Hall A1
8:30 S-30
Recent insights
in schizophrenia
physiopathology
and treatments
S-31
Duration of
untreated
psychosis: From
neuroimaging to
clinical trials
S-32
New per-
spectives on
transcranial
magnetic
stimulation
in psychiatric
disorders
S-33
Epigenetic
biomarkers for
the diagnosis of
mood disorders
S-34
Sex hormones
and their
wide-ranging
effects on psy-
chopathology
WS-05
Gesture as
window to
psychosis
pathobiology:
From aberrant
body experience
to social inter-
action
S-35
New insights
into the
neurobiology
and treatment
aspects of OCD
comorbid with
schizophrenia
and bipolar
disorder
9:00
9:30
10:00
Coffee Break
PL-02
Ketamine in
mood disorders
10:30
11:00
D-02
The Research
Domain Criteria
(RDoC) can
create a new
kind of taxono-
my holding
greater promise
compared to the
traditional ...
TFS-04
Sleep in
depression and
cognition – from
research to clini-
cal practice
S-36
The role of
the nucleus
accumbens in
psychiatry
S-37
Neurobiologic
imaging
studies of mood
disorders, neu-
rogenetics and
antidepressant
action with posi-
tron emission
tomography
S-38
Treatment resis-
tant schizophre-
nia: Definitions,
psychobiology
and clinical
treatment
WS-06
Neurobiology
of suicidal
behaviour
WS-08
Functional neu-
roanatomy of
hallucinations
11:30
12:00
12:30
13:00
Guided
Poster Tours
P-06 – P-10
SA-02
Actelion
Satellite
Symposium
13:30
14:00
ES-02
Pharmacolog-
ical treatment
and non-invasive
brain stimu-
lation
14:30
15:00
WS-07
Merging
evidence and
clinical practice
in management
of depression:
The CANMAT
experience
TFS-05
Biomarkers
for schizo-
phrenia: From
molecules to
brain function.
A consensus of
the WFSBP Task
Force on biolo-
gical markers
TFW-02
WFSBP Con-
sensus on the
management
of agitation in
psychiatry
S-39
Current research
on the use of
cannabinoids
S-40
Alzheimer's
Disease (AD)
pathophysiolo-
gy, prevention
and treatment
strategies:
Where we stand
and where we
go?
S-41
Electroconvul-
sive therapy
for depression
– optimising
treatment and
maintaining
recovery
15:30
16:00
16:30
Coffee Break
17:00 S-66
NMDA receptor
antagonists in
psychiatry
S-42
Neuroepigenetic
approaches to
assess disease
risk, mechanism
and treatment
TFS-06
Electroconvul-
sive therapy:
Beyond depres-
sion
FC-06
Antipsychotics 1
FC-07
Anxiety &
PTSD
FC-08
Depression 2
17:30
18:00
18:30
Registration Counter
08:00–18:30
Poster Exhibition
09:00–17:00
Technical Exhibition
09:00–17:00